US Bancorp DE Cuts Stock Position in Teleflex Incorporated $TFX

US Bancorp DE lowered its holdings in Teleflex Incorporated (NYSE:TFX) by 14.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,532 shares of the medical technology company’s stock after selling 908 shares during the period. US Bancorp DE’s holdings in Teleflex were worth $655,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. CX Institutional boosted its position in Teleflex by 14.7% in the second quarter. CX Institutional now owns 872 shares of the medical technology company’s stock worth $103,000 after purchasing an additional 112 shares during the last quarter. Signaturefd LLC boosted its position in Teleflex by 38.3% in the first quarter. Signaturefd LLC now owns 433 shares of the medical technology company’s stock worth $60,000 after purchasing an additional 120 shares during the last quarter. Empirical Finance LLC boosted its position in Teleflex by 7.9% in the first quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company’s stock worth $234,000 after purchasing an additional 124 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Teleflex by 30.2% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 556 shares of the medical technology company’s stock worth $77,000 after purchasing an additional 129 shares during the last quarter. Finally, HighTower Advisors LLC boosted its position in Teleflex by 2.7% in the first quarter. HighTower Advisors LLC now owns 5,102 shares of the medical technology company’s stock worth $705,000 after purchasing an additional 133 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on TFX. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Teleflex in a research report on Wednesday, October 8th. Zacks Research cut Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Wall Street Zen cut Teleflex from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 15th. Wells Fargo & Company dropped their price target on Teleflex from $137.00 to $131.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Finally, Mizuho upped their price target on Teleflex from $130.00 to $135.00 and gave the company a “neutral” rating in a research report on Friday, August 1st. One analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $141.57.

Teleflex Stock Performance

NYSE:TFX opened at $128.44 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41. Teleflex Incorporated has a 52-week low of $108.90 and a 52-week high of $241.41. The firm has a market cap of $5.68 billion, a price-to-earnings ratio of 30.22, a PEG ratio of 1.79 and a beta of 1.05. The business’s fifty day moving average is $125.09 and its 200 day moving average is $123.52.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The company had revenue of $780.90 million for the quarter, compared to analyst estimates of $771.53 million. During the same period in the previous year, the company posted $3.42 EPS. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. Research analysts predict that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 15th. Shareholders of record on Friday, August 15th were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date was Friday, August 15th. Teleflex’s dividend payout ratio is currently 32.00%.

Insiders Place Their Bets

In other Teleflex news, CEO Liam Kelly bought 1,500 shares of the firm’s stock in a transaction on Tuesday, August 5th. The shares were acquired at an average cost of $115.07 per share, for a total transaction of $172,605.00. Following the purchase, the chief executive officer directly owned 45,267 shares of the company’s stock, valued at $5,208,873.69. The trade was a 3.43% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Andrew A. Krakauer bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 5th. The stock was acquired at an average price of $115.25 per share, for a total transaction of $115,250.00. Following the completion of the purchase, the director directly owned 7,192 shares in the company, valued at approximately $828,878. The trade was a 16.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 5,500 shares of company stock worth $633,590. 1.40% of the stock is owned by corporate insiders.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.